ForumIAS LATEST
- FRC 2027: SFG Residential program | accepting application for Tranche-2 Click Here to know more →
- CSAT Classes for Prelims 2027 by Rishi Bhargav sir starts 16 Nov. at 5 PM Click Here to know more →
- Prelims Sprint classes 2027: Starts 2nd Nov. at 4:30 PM | First class open to all. Click Here to know more →
News: WHO has endorsed a new class of drug, GLP-1 Receptor Agonists, for managing obesity.
About GLP-1 Receptor Agonists
- Role: They mimic a hormone that regulates appetite and blood sugar level, lipid metabolism, and other biological functions.
- Drugs in this class include semaglutide and tirzepatide, which have potential to be transformative.
- Utility:
- Helps in treatment of Type 2 diabetes and obesity.
- These drugs can complement current policies promoting healthy eating and physical exercise to curb the obesity pandemic.
- These drugs are significant as obesity affects nearly 1 in 8 people worldwide.
- Side Effects: There are severe side effects like stomach paralysis, inflamed pancreas and thyroid cancer.
